Aprea Therapeutics shares rise 11.29% premarket after closing $30 million oversubscribed private placement to fund APR-1051 development.

Aprea Therapeutics surged 11.29% in premarket trading following the announcement that it closed an oversubscribed $30 million private placement led by Soleus Capital and other new and existing investors. The financing will support the ongoing development of its lead candidate, APR-1051, including expansion of the ACESOT-1051 trial into specific biomarker-defined tumor populations. The company also reported early clinical activity in the trial, further reinforcing investor optimism. The capital raise is expected to extend its cash runway into early 2028, reducing near-term financial pressure and signaling strong investor confidence in Aprea’s precision oncology platform.